Braun Stacey Associates Inc. Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Braun Stacey Associates Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 5.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,964 shares of the medical research company’s stock after selling 2,992 shares during the quarter. Braun Stacey Associates Inc.’s holdings in IQVIA were worth $11,840,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. 1832 Asset Management L.P. raised its stake in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA in the 2nd quarter worth about $70,610,000. Impax Asset Management Group plc increased its stake in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after purchasing an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in IQVIA by 285.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock valued at $56,783,000 after purchasing an additional 198,808 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IQV. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, Truist Financial decreased their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Price Performance

NYSE IQV opened at $192.68 on Monday. The stock has a market capitalization of $34.97 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51. The company has a 50 day moving average price of $226.95 and a two-hundred day moving average price of $228.24. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $189.63 and a 12-month high of $261.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.